p14ARF, p15INK4b, and p16INK4a methylation status in chronic myelogenous leukemia [5]

Blood

Volumn 101, Issue 1, 2003, Pages 374-375

  Kusy, Sophie ^a   Cividin, Marie ^a   Sorel, Nathalie ^a   Brizard, Fraņoise ^a   Guilhot, François ^a   Brizard, André ^a   Larsen, Chrstìan ^a   Roche, Joëlle ^a  

^a IBMIG Institut de Biologie Moleculaire et dIngenierie Genetique   (France)

Author keywords

[No Author keywords available]

Indexed keywords

PROTEIN P14; PROTEIN P15; PROTEIN P16; CDKN2B PROTEIN, HUMAN; CELL CYCLE PROTEIN; CYCLIN DEPENDENT KINASE INHIBITOR 2B; PROTEIN P14ARF; PROTEIN P16INK4A; TUMOR SUPPRESSOR PROTEIN;

CHROMOSOME 9P; CHRONIC MYELOID LEUKEMIA; GENE CONTROL; GENE INACTIVATION; GENE SILENCING; HUMAN; LETTER; METHYLATION; PRIORITY JOURNAL; PROMOTER REGION; DNA METHYLATION; GENETICS;

CELL CYCLE PROTEINS; CYCLIN-DEPENDENT KINASE INHIBITOR P15; CYCLIN-DEPENDENT KINASE INHIBITOR P16; DNA METHYLATION; HUMANS; LEUKEMIA, MYELOID, CHRONIC; PROMOTER REGIONS (GENETICS); TUMOR SUPPRESSOR PROTEIN P14ARF; TUMOR SUPPRESSOR PROTEINS;

EID: 0037207526     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood-2002-09-2834     Document Type: Letter

References (9)

1. Esteller M, Fraga MF, Guo M, et al. DNA methylation patterns in hereditary human cancers mimic sporadic tumorigenesis. Hum Mol Genet. 2001;10:3001-3007.
2. Herman JG, Civin CI, Issa JP, et al. Distinct patterns of inactivation of p151NK4B and p161NK4A characterize the major types of hematological malignancies. Cancer Res. 1997;57:837-841.
3. Nguyen TT, Mohrbacher AF, Tsai YC, et al. Quantitative measure of c-abl and p15 methylation in chronic myelogenous leukemia: Biological implications. Blood. 2000;95:2990-2992.
4. Herman JG, Graff JR, Myohanen S, Nelkin BD, Baylin SB. Methylation-specific PCR: A novel PCR assay for methylation status of CpG islands. Proc Natl Acad Sci U S A. 1996;93:9821-9826.
5. Guilhot F, Chastang C, Michallet M, et al. Interferon alfa-2b combined with cytarabine versus interferon alone in chronic myelogenous leukemia. N Engl J Medicine. 1997;337:223-229.
6. Kantarjian H, Sawyers C, Hochhaus A, et al. Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia. N Engl J Medecine. 2002;346:645-652.
7. Esteller M, Tortola S, Toyota M, et al, Hypermethylation-associated inactivation of p14(ARF) is independent of p16(INK4a) methylation and p53 mutational status. Cancer Res. 2000;60:129-133.
8. Wong IH, Ng MH, Huang DP, Lee JC. Aberrant p15 promoter methylation in adult and childhood acute leukemias of nearly all morphologic subtypes: Potential prognostic implications. Blood. 2000;95:1942-1949,
9. Tien HF, Tang JH, Tsay W, et al. Methylation of the p15(INK4B) gene in myelodysplastic syndrome: It can be detected early at diagnosis or during disease progression and is highly associated with leukaemic transformation. Br J Haematol. 2001;112:148-154.